SecBot SecBot

SMMT drug pipeline

Summit Therapeutics Inc. · 1 rated drug
$11.82
−16.5% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.7%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
1
1 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhaseFiled/PDUFA (BLA under FDA review); also multiple ongoing Phase 3 trials
Time to marketIf approved, potential US launch in late 2026 or early 2027. Already approved in China (May 2024).

ivonescimab Updated Jun 30

What to watch

The November 14 PDUFA is the defining event. The HARMONi global trial showed statistically significant PFS but OS missed the pre-specified threshold, an unusual situation that creates binary risk on approval odds. Watch for an FDA Advisory Committee date (if scheduled) as a pre-decision signal. Also watch HARMONi-3 final PFS readout (2H 2026) as a secondary catalyst. The $500M June offering diluted existing holders but extended the cash runway, and the massive insider buying (~$100M from co-CEOs at ~$13.12) signals conviction at current levels.

Bull case
  • First-in-class PD-1/VEGF bispecific, the only one to complete Phase 3 validation globally, with a potential mechanistic advantage over combining two separate antibodies
  • HARMONi-6 delivered statistically significant OS benefit (HR=0.66, 34% risk reduction) presented at ASCO 2026 plenary, proving the drug can beat PD-1+chemo
  • Massive insider buying: co-CEOs Robert Duggan and Mahkam Zanganeh purchased ~$100M total at ~$13.12/share on June 12, 2026, a strong conviction signal near the 52-week low
Bear case
  • OS data is mixed and controversial: the global HARMONi trial's OS missed the pre-specified threshold, HARMONi-2's OS (vs Keytruda monotherapy) was negative, and only HARMONi-6 (China-only data) showed positive OS
  • Interim PFS analysis of HARMONi-3 (the pivotal US registration trial vs Keytruda+chemo) missed the early statistical bar, raising questions about whether the drug can beat the current standard of care in Western patients
  • $500M dilutive public stock offering announced June 9, 2026 sent shares to a 52-week low of $12.55; existing holders were significantly diluted

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Jan 31, 2026ivonescimabBLA filed−2.9%+3.5%
Jan 29, 2026ivonescimabBLA filed−7.4%−11.4%
Jan 1, 2026ivonescimabBLA filed+0.2%+7.7%
Sep 1, 2025ivonescimabBLA filed+0.6%−17.9%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
RidinilazoleComparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile InfectionPhase 3Completed · results759Nov 17, 2021